Kangfang Biological first global multicenter phase III clinical study results announced: has reached the primary endpoint.

On September 7th, CanFi Biotech announced the updated data of the first global multicenter Phase III clinical study HARMONi of camrelizumab at the World Lung Cancer Conference. The study evaluated the efficacy and safety of camrelizumab combined with chemotherapy in patients with disease progression after third-generation EGFR-TKI treatment. The results showed a significant improvement in overall survival data with a median follow-up time of 13.7 months, and highlighted survival benefits in the North American population. Camrelizumab is the world's first PD-1/VEGF dual-targeted drug. Last year, in a domestic Phase III clinical study of camrelizumab in first-line treatment of PD-L1 positive non-small cell lung cancer as a monotherapy, its PFS was longer than pembrolizumab's PD-1 monotherapy, showing potential to replace Keytruda. Camrelizumab has become the hottest dual-targeted drug worldwide since its debut.